Navigation Links
Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors
Date:1/15/2014

OXFORD, England and SAN JOSE, California, January 15, 2014 /PRNewswire/ --

Oxford BioTherapeutics, an international biotechnology company developing antibody-drug conjugates for cancer, today announced the appointment of Thomas C Reynolds MD, PhD to its Board of Directors. Dr Reynolds has over 20 years' development experience gained in the biotechnology industry, most recently as Chief Medical Officer at Seattle Genetics.

"I am delighted to welcome Tom at this transformative time for Oxford BioTherapeutics, as the company completes its transition into a fully-fledged oncology product development business," said Bryan Morton, Chairman of Oxford BioTherapeutics. "Dr Reynolds' experience in the oncology field will prove invaluable as we progress our pipeline into the clinic, and in particular his expertise in bringing antibody-drug conjugates to market having led the development and approval of ADCETRIS at Seattle Genetics."

Commenting on his appointment, Thomas C Reynolds MD, PhD, said, "I am highly impressed with Oxford BioTherapeutics' cancer targeting technology, which has continued to mature since my tenure at Seattle Genetics. I am delighted to be able to contribute to the development of the company's exciting antibody-based oncology products."

About Thomas C Reynolds MD, PhD

Dr Reynolds has held a number of senior development roles during his career of over 20 years in the biotechnology industry. Most recently he was Chief Medical Officer at Seattle Genetics, where he had direct oversight of the development and approval of the company's antibody-drug conjugate, ADCETRIS. Prior to this, he was Vice President for Medical Affairs at Zymogenetics, having held the role of Senior Medical Director. Previously, he held a number of senior roles at Targeted Genetics Corporation, culminating in the position of Vice President, Clinical A
'/>"/>

SOURCE Oxford BioTherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxford University Press to publish BioScience journal starting in 2014
2. Oxford BioMedica Announces Update from ARVO 2013
3. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
4. Oxford Performance Materials and Biomet Microfixation Join Forces
5. Oxford University Hospitals NHS Trust and the Bodleian Libraries Select ClinicalKey
6. Oxford Finance Completes $271.4 Million Securitization Transaction
7. Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
8. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
9. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
10. Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease
11. Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Richardson, Texas (PRWEB) October 20, 2014 ... today announced that a team from Iowa State University ... * design contest. Using a Convey HC-2ex, the team’s ... than 14 times faster than the second place finisher. ... academic world embarked upon the month long challenge, using ...
(Date:10/20/2014)...  GenVec, Inc. (NASDAQ: GNVC ) today announced ... its board of directors effective on October 24, 2014.   Dr. ... as its chairman from June 2006 to November 2013.  During ... Governance and Audit Committees of the board.  ... dedicated service to GenVec, and its stockholders," said Wayne ...
(Date:10/20/2014)... OR (PRWEB) October 20, 2014 Local ... participate in an investigational study of donor stem cells ... in stem cell therapy and has performed clinical stem ... this study is to determine if a single injection ... affected joints can help reduce pain and inflammation in ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The ... bromine market in Asia-Pacific with analysis and forecast ... the Asia Pacific Bromine Market report, to get ... also provides a glimpse of the segmentation in ... various tables and figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... Galenea Corp. and,Otsuka Pharmaceutical Co., Ltd. announced ... development collaboration. The two companies have,been working together ... for schizophrenia and other central nervous system (CNS),diseases. ... extension of the initial,five-year alliance and brings the ...
... PRINCETON, N.J., Oct. 3 Covance Inc. (NYSE:,CVD), ... drug development,services companies, today announced that it has ... provide a broad-range of drug development services,over the ... early drug,development campus in Greenfield, Indiana. Effective midnight ...
... AUSTIN, Texas and TORONTO, Oct. 3 Two ... to integrate vibration,therapy into the stem cell harvesting ... company based in Austin,Texas, has signed an exclusive ... of Toronto, Ontario. The partnership,between the two companies ...
Cached Biology Technology:Galenea and Otsuka Pharmaceutical Extend & Expand Schizophrenia Research Collaboration 2Galenea and Otsuka Pharmaceutical Extend & Expand Schizophrenia Research Collaboration 3New Partnership Integrates Vibration Therapy Into Stem Cell Procedures 2New Partnership Integrates Vibration Therapy Into Stem Cell Procedures 3
(Date:10/18/2014)... and stress-related psychiatric disorders are associated with ... molecular mechanisms underlying this relation are unknown. ... development of targeted preventive strategies and new ... This work is presented at the European ... an international group of researchers from Germany ...
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
(Date:10/16/2014)... Melbourne researchers have challenged conventional thinking on how the ... new mechanism for how bowel cancer starts. , The ... maintaining and regenerating the ,crypts, that are a feature ... are involved in bowel cancer development, a controversial finding ... existence. , Using 3D imaging technologies, Dr Chin Wee ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2
... Va. -- The USDA,s National Institute of Food and ... of Agriculture and Life Sciences at Virginia Tech to ... wine quality in the eastern United States. According ... the five-year project seeks to create, refine, and encourage ...
... REDWOOD SHORES, Calif., Oct. 27 ... ... lpUnit=,PRN,; --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... New Delhi, India, October 27, 2010 -- Research teams ... on two continents have come together to form the ... classes of antimalarials. This bold initiative will develop ... in desperate need of new treatments. Malaria ...
Cached Biology News:USDA awards Virginia Tech $3.8 million to stimulate eastern US wine industry 2CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 2CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 3CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 4CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 5CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 6CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 7CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 8CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 9CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand 10International malaria research consortium tackles deadly disease 2International malaria research consortium tackles deadly disease 3
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
... with Purpose -- The Varian ... the highest level of flexibility ... an affordable, easy-to-use system. The ... workstation guarantees success with today's ...
Homo sapiens 4-aminobutyrate aminotransferase Antigen: Recombinant Protein...
Human DCIR/CLEC4A Phycoerythrin MAb (Clone 216110)...
Biology Products: